The pandemic has led pharma marketers to embrace digital marketing communications and the benefits of investing in telehealth platforms to engage physicians are numerous and provide a tremendous opportunity.
Clinical data quashes experimental Covid-19 therapies from Brii, Vir & Apellis
Antibody therapies from Brii Biosciences and Vir Biotechnology failed to show sufficient efficacy to advance to the next stage of an NIH-sponsored Covid-19 clinical trial. Apellis Pharmaceuticals and Durect also stopped work on experimental Covid treatments.
Shares0
Drug developers are still trying different approaches to treating Covid-19 but clinical trial results this week halted several potential therapies, including two that are part of a National Institutes of Health program evaluating treatments for hospitalized patients.
The NIH’s Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) program launched to speed up the development and testing of treatments and vaccines. The study uses an adaptive two-stage design for the Phase 3 test. A treatment that demonstrates safety in stage 1 can proceed to stage 2, following review by an independent board.
Hillrom axed plans to acquire cardiac monitoring company Bardy Diagnostics over reimbursement changes by a Medicare contractor. Bardy filed suit against Hillrom on Sunday.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.